Improving the way we measure treatment success in acute graft versus host disease
Official title: Validation of a novel and more accurate endpoint for GVHD clinical trials
Funded at Icahn School of Medicine at Mount Sinai · NIH-11032473 · Data updated 2026-11-12
This study is testing a new way to track how well treatments are working for people with acute graft versus host disease (GVHD) after a stem cell transplant, using blood tests to help predict long-term recovery based on symptoms at the start and two weeks after treatment.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | January 15, 2025 |
| Project end | January 14, 2027 |
| Funding year | 2025 |
| Award (this year) | $126,750 |
| NIH project number | 1R21HL177578-01 |
| Project ID | NIH-11032473 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who have undergone allogeneic hematopoietic cell transplantation and are experiencing symptoms of acute graft versus host disease.
✕Less likely to help
Patients who are not undergoing treatment for acute graft versus host disease or those with chronic forms of the disease may not benefit from this research.
What this research studies
This research aims to validate a new method for assessing treatment outcomes in patients with acute graft versus host disease (GVHD), a serious condition that can occur after blood stem cell transplantation. The study will utilize serum biomarkers to create a risk score that better predicts long-term patient outcomes by taking into account the severity of symptoms at the onset of the disease and at two weeks after treatment. By addressing the limitations of current measurement methods, this research seeks to provide a more accurate evaluation of treatment effectiveness. Patients may be monitored closely to gather data that will help refine this new approach.
Why it matters
Potential benefit: If successful, this research could lead to more accurate assessments of treatment effectiveness, ultimately improving patient care and outcomes for those suffering from acute GVHD.
How similar studies have gone: Previous research has shown promise in using biomarkers for assessing treatment outcomes in similar conditions, suggesting that this approach may be effective.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Levine, John — Icahn School of Medicine at Mount Sinai
- Study coordinator: Levine, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.